Association between physical activity and risk of prevalent psoriasis

A MOOSE-compliant meta-analysis

Qi Zheng, MD^a, Xiao Ying Sun, MD^b, Xiao Miao, MD^a, Rong Xu, MD, PhD^a, Tian Ma, MD, PhD^a, Ya Nan Zhang, MD, PhD^a, Hong Jin Li, MD, PhD^b, Bin Li, MD., PhD^{a,b,*}, Xin Li, MD^{a,b,*}

Abstract

Psoriasis is a common chronic relapsing immune-mediated inflammatory disease, whose prevalence has increased in recent years. Some physicians believe that physical activity is associated with numerous health-related benefits in adults with dermatoses. While numerous studies have suggested an association between psoriasis and physical activity, others have yielded contradictory results. The aim of our study was to evaluate the association between the level of physical activity and prevalence of psoriasis.

A comprehensive search of the literature was performed from January 1970 to February 2017 using EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials electronic databases. Studies published in English were reviewed to identify the contribution of intensity of physical activity on the prevalence of psoriasis.

The search strategy yielded 1100 relevant studies, among which 13 observational studies were included. We found that patients with psoriasis exercise significantly less vigorously than controls (relative risk [RR]: 0.76; 95% confidence interval [Cl]: 0.67–0.85; P < .00001). Predominantly, these patients exercised at moderate intensity (RR: 0.40; 95% Cl: 0.18–0.90; P = .03). Some patients had lesser degree of movement, and some exercised strenuously. There were no significant differences observed in the intensity of exercise performed by controls (RR: 0.90; 95% Cl: 0.46–1.77; P = .76). The 3 studies found the frequency of regular exercise differed significantly between patients with psoriasis and controls (RR: 0.88; 95% Cl: 0.82–0.95; P = .0007).

Different severities of psoriasis have different influences on patients' physical activity levels. Patients with a higher proportion of psoriatic lesions and self-awareness were associated with lower-intensity exercises. Our meta-analysis highlights the fact that intense physical activity may lower the prevalence of psoriasis.

Abbreviations: CENTRAL = the Cochrane Central Register of Controlled Trials, CI = confidence interval, COPD = chronic obstructive pulmonary disease, RR = risk ratio, SMD = standardized mean difference.

Keywords: exercise, physical activity, psoriasis, quality of life

Editor: Angelo Valerio Marzano.

The review protocol for this study was registered with the PROSPERO database before beginning the review process (CRD42016045904).

The study was funded by Shanghai Rising-Star Program (no. 16QA1403800); National Science Foundation (NSFC) of China (nos. 81473682, 81673977 and 81302971); Development Fund for Shanghai Talents (no. 2017047); Young Talent Supporting Program of China Association of Traditional Chinese Medicine (QNRC2-B05); and Shanghai Shen Kang Hospital Development Center Project (no. 16CR2035B).

The authors have no conflicts of interest to declare.

^a Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, ^b Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China.

^{*} Correspondence: Xin Li and Bin Li, Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, 110 Ganhe Road, Shanghai 200437, China (e-mails: 13661956326@163.com; 18930568129@163.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2018) 97:27(e11394)

Received: 7 December 2017 / Accepted: 12 June 2018 http://dx.doi.org/10.1097/MD.000000000011394

1. Introduction

Psoriasis is a common chronic immune-mediated inflammatory disease that affects 2% to 4% of the population in western countries.^[1] Psoriasis adversely affects patients' quality of life, and can also result in a significant financial burden for those affected.^[2] The underlying pathogenesis of psoriasis is yet to be completely elucidated. Therefore, conducting appropriate studies and the development of appropriate clinical therapies are key target areas for dermatologists. Recent studies have already shown that moderate-to-severe psoriasis is associated with an increased risk of comorbidities including obesity,^[3,4] cardiovascular diseases,^[5] type 2 diabetes,^[6] hypertension,^[7] myocardial infarction,^[8] cancer,^[9] osteoporosis,^[10,11] avascular necrosis,^[12] metabolic syndrome,^[13] chronic obstructive pulmonary disease (COPD),^[14] hyperurice-mia,^[15] obstructive sleep apnea,^[16] and lipid abnormalities.^[17]

Modern medicine believes that exercising is advantageous to the body. Indeed, long-term moderate exercise can help people feel young and energized. It is commonly known that physical activity is associated with preventive as well as therapeutic health-related benefits for a range of chronic diseases in both patients and the general population. Research has shown that exercise leads to a range of benefits for patients in relation to obesity,^[18] cardiovascular disease, musculoskeletal health,^[19,20] type 2 diabetes, 20 inflammatory biomarkers,^[21,22] cancer,^[23] wound healing,^[24] and emotional state.^[25] Several studies have investigated the relationship between physical activity and psoriasis, and some of these studies have found contradictory data.^[26–30] Some scholars believe that physical activity is likely to aggravate the severity of psoriasis, while others believe that psoriasis is likely to improve following a course of voluntary exercise. In our clinic, a large number of patients with psoriatic skin symptoms and mental health problems (anxiety, tension, low self-esteem, isolation, and depression) showed improvements in their condition following varying degrees of physical activity.^[31,32] In the present study, we performed a meta-analysis of studies published over the last 47 years that have investigated the correlation between the risk of psoriasis and intensity of physical activity. The purpose of this study was to elucidate the potential underlying association between the intensity of physical activity and the risk of prevalent psoriasis.

2. Materials and methods


2.1. Data sources and searches

To investigate the relationship between physical activity and psoriasis, 3 reviewers (QZ, XS, and XM) systematically searched

EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials (CENTRAL) electronic databases for relevant publications using the following keywords: (psoriasis OR physical activity), (psoriasis OR exercise), (psoriasis OR movement), and (psoriasis OR sports). Our search included publications written in English and dated from January 1970 to February 2017.

2.2. Study selection

In order to identify relevant articles, we screened abstracts for the following criteria: randomized controlled trials and observational studies; studies dedicated to the relationship between psoriasis and physical activity; and studies assessing the impact of physical activity upon quality of life. If an article satisfied these criteria, regardless of the participants' age, gender, or nationality, we then applied a second phase (Level 2) filter, which purposefully selected articles that were specifically related to humans, and those that featured a significant amount of original data (thus allowing us to extract data for calculation). We deleted 218 duplicated publications, leaving 95 articles that met the selection criteria required by our Level 1 filter. Subsequently, we selected 13 articles that met all the inclusion criteria for the final meta-analysis,^[9,17,33–43] as shown in Figure 1 (Table 1).





Observationa	I studies inclu	Observational studies included in the meta-analysis.										
			Tatal	Totol	Number of regular physical	Number of regular physical	Mean exercise	Mean exercise	Different intracity	Different	Mean exercise	Mean exercise
Reference, year	Study design	Objective	number of cases	number of controls	of cases, %	of controls, %	of cases (SD)	of controls (SD)	of cases, n/%	of controls, n/%	cases (SD)	of controls (SD)
Torres et al (2014) ^[37]	Case-control study	To analyze and compare physical activities undertaken by patients with severe psoriasis and heattry controls, using the International Physical Activity Questionnaire-Short Form	06	160			3341.5 (3096.8)	4688.7 (3186.1)	low: 17 (18.9) moderate: 46 (51.1) vigorous: 44 (48.9)	low: 10 (6.3) moderate: 60 (37.6) vigorous: 100 (62.4)		
Do et al (2015) ^{(35]}	Cohort study	To examine the association of the extent of psoriatic skin lesions with the likelihood of participating in leisure-time moderate-to- vigorous physical activity (MVPA) and metabolic equivalent task (MET)-minutes of MVPA	158	6011	102 (65.5)	4189 (69.7)						
Demirel et al (2013) ^[39]	Case-control study	To compare the aerobic exercise capacity, daily physical activity, pulmonary functions, resting metabolic rate, and body composition parameters in patients with psoniasis with those in basitiv controls	30	30							91.4 (10.5)	89.8 (10.6)
Balato et al (2015) ^[34]	Case-control study	To investigate the relationship between psoriasis and physical activity.	400	498			4.0 (10.3)	4.2 (9.3)	low: 18 (4.5) moderate: 14 (3.5)	low: 55 (11) moderate: 29 (5.8)		
Frankel et al (2012) ^[40]	Cohort study.	To examine the association between total physical activity, walking, and vigorous exercise, and the incidence of psoriasis in women.	1068	85587					wgdraus. 12 (3) Iow: 222 (20.8) moderate: 684 (64) viaorous: 162 (15.2)	viguruus. zz (4.4) low: 16739 (19.6); moderate: 51839 (60.6); vicorous: 17007 (19.9)		
Prizment et al (2011) ^[9] Kavli et al (1985) ^[41]	Cohort study Cohort study	To determine if psoriasis in women over 65 years was associated with the incidence of cancer. To examine the associations between psoriasis prevalence and environmental risk factors.	719 14667	32191	261 (36.3)	13552 (42.1)			low: 175141 (10.5) moderate: 8389 (18.1) viorone: 031 /7 0)			
Osmancevic et al (2008) ^[36]	Case-control study	To examine bone density in postmenopausal women with psoriasis exposed to regular ultraviolet B therapy to estimate the influence of the barrow of bone actions to bone actions of the barrow of bone actions to bone actions of the barrow of bone actions actions of the barrow of bone actions of the barrow of barrow of bone actions of the barrow of ba	35	2448							3.7 (2.2)	1.8 (1.0)
Ahdout et al (2012) ^[33]	Case-control study	OI TISK Lacus on Dolle stauts. To evaluate modifiable iffestlyle factors including stress level, physical activity, and nutrition, which may be associated with metabolic sunctrome in partients with pervises.	65	52							32.42 (22.99)	40.80 (25.36)
Wilson et al (2013) ^[38]	Case-control study	To compare physical activity between individuals with and without psortais as well as explore the associations between measures of psortaiss severity and physical activity.	117	4199			24 (17.3)	27.7 (51.8)				
Mallbris et al (2006) ^[17]	Case-control study	To compare the plasma lipid, lipoprotein, and apolipoprotein profile in patients with onset of psoriasis within the past 12 mo with that of closely matched controls	200	285	102 (51)	158 (56)						
Milčić et al (2017) ^[43]	Case-control study	To example the prevalence of metabolic syndrome and its components in patients with psoriasis, and to assess which factors may negligit metabolic syndrome in these patients	244	163					low: 147 (60.2) moderate: 71 (29.1) vigorous: 26 (10.7)	low: 70 (42.9) moderate: 66 (40.5) vigorous: 27 (16.6)		
Barrea et al (2015) ^{(42]}	Case-control study	To compare the dietary intake, anthropometric measurements, and cardio-metabolic risk profile between male psoriatic patients and healthy control subjects matched by age and BMI.	41	41					Iow: 39 (95) moderate: 2 (5)	low: 36 (87.8) moderate: 3 (12.2)		

Table 1

2.3. Data extraction and quality assessment

Descriptive data from each selected study were independently collated by 3 reviewers (QZ, XS, and XM), including the first author; study characteristics (ie, year, objective, and design); participant characteristics (ie, the numbers of patients and controls, and the number of males); and outcome characteristics (ie, exercise minutes and exercise scores for cases and controls, and the frequency of subjects undertaking different intensities of physical activity in the case and control groups). Scores on the Newcastle–Ottawa Scale^[44] ranged from 7 to 9, as shown in Table 2. Specifically, 9 studies were regarded as high-quality (8–9 stars) and 4 as medium-quality studies (>6 stars).

2.4. Data synthesis and analysis

The primary outcomes of our analysis of each study were as follows: the different levels of physical activity between healthy controls and patients with psoriasis; and the association between level of physical activity and the risk of psoriasis. Furthermore, we used 2 parameters (exercise minutes and exercise score) as measurable indicators of physical activity. The degree of heterogeneity between the studies was assessed using I^2 tests. An I^2 value >50% was considered to indicate abundant heterogeneity. Randomized-effect models were used to compute standardized mean difference (SMD) and risk ratio (RR) values. Otherwise, when I^2 was <50%, we considered that the study heterogeneity was not substantial and a fixed-effect model was suitable. To investigate the possible explanations for heterogeneity, we performed subgroup analysis using prespecified variables and randomized-effects meta-analysis. Review Manager 5.2 software was used for all meta-analysis (http://ims. cochrane.org/revman).

2.5. Ethics and disseminations

Ethical approval is not required in this study because the data used include peer-reviewed publications, which do not comprise any information that could identify subjects.

3. Results

This meta-analysis combined data of 13 studies including a total of 149,499 participants. A total of 17,834 patients served as the

experimental group, and 131,665 normal people comprised the control group. After merging the relevant data, we divided the intensity exercise into 3 categories: low, moderate, and vigorous.

There was no significant difference in the level of exercise between people without and with psoriasis when analyzed for the overall effect (Fig. 2) (RR: 0.89; 95% CI: 0.78–1.03; P=.11). However, subgroup analysis showed that patients with psoriasis performed vigorous exercises significantly less than controls (RR: 0.76; 95% CI: 0.67–0.85; P < .00001). Figures 3 and 4 show that there was no significant difference in terms of exercise duration (SMD: -0.15; 95% CI: 0.36–0.06; P=.17) or exercise scores (SMD: 0.56; 95% CI: -0.89 to 2.01; P=.44) between patients with psoriasis and controls.

When comparing different intensities of exercise (Fig. 5), it is evident that moderate exercise was the most predominant intensity of exercise in patients with psoriasis (RR: 0.40; 95% CI: 0.18–0.90; P=.03). A total of 5584 patients showed a lower degree of movement compared to 1165 patients who carried out strenuous exercises. However, when we compared different intensities of physical activity in people without psoriasis (Fig. 6), we failed to observe any significant relationship; neither in terms of the overall effect (RR: 0.90; 95% CI: 0.46–1.77; P=.76) nor in the following subgroup analysis, including a comparison between low, moderate, and vigorous intensities (vigorous vs low, RR: 1.09; 95% CI: 0.43–2.75; P=.86; moderate vs low, RR: 1.04: 95% CI: 0.41–2.63; P=.93; vigorous vs moderate, RR: 0.64; 95% CI: 0.25–1.64; P=.35).

Figure 7 shows that the frequency of regular exercise differed significantly between patients with psoriasis and controls (RR: 0.88; 95% CI: 0.82–0.95; P=.0007). By comparing the daily amount of regular exercising performed before suffering from psoriasis, we found that the number of patients was lower than the controls.

4. Discussion and conclusions

Psoriasis is a recurrent incurable inflammatory disease with complex etiology. Prospective studies^[3] have demonstrated that infections, immune dysfunctions, metabolic disorders, and emotional fluctuations are pathogenic factors in psoriasis. In additional, alcohol intake,^[45] smoking,^[46] obesity,^[47] and fatigue^[48] are risk factors of psoriasis. However, relatively fewer

_		

Newcastle-Ottawa	Scale	(NOS)	Quality	Assessment	Table.

Study	Selection	Comparability	Exposure/Outcome	Overall star rating
Torres et al (2014) ^[37]	****	36 ak	***	9
Do et al (2015) ^[35]	****	**	34:34:34:	9
Demirel et al (2013) ^[39]	***	**	36-36-36	8
Balato et al (2015) ^[34]	**	**	***	7
Frankel et al (2012) ^[40]	***	**	***	8
Prizment et al (2011) ^[9]	***	**	***	8
Kavli et al (1985) ^[41]	***	**	***	8
Osmancevic et al (2008) ^[36]	***	**	**	7
Ahdout et al (2012) ^[33]	***	***	***	8
Wilson et al (2013) ^[38]	***	**	***	8
Mallbris et al (2006) ^[17]	***	**	**	7
Milčić et al (2017) ^[43]	**	**	***	7
Barrea et al (2015) ^[42]	****	**	**	8

Methodological Quality Assessment by the Newcastle-Ottawa Scale (NOS). Each asterisk $(^{*})$ denotes one point on the NOS.

	Psoria	sis	Con	trol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% CI	M-H, Random, 95% CI
1.1.1 vigorous level							
Balato 2015	12	400	22	498	3.0%	0.68 [0.34, 1.36]	
Frankel 2012	162	1068	17007	85587	11.2%	0.76 [0.66, 0.88]	-
Milčić 2017	26	244	27	163	4.7%	0.64 [0.39, 1.06]	
Torres 2014	44	90	100	160	9.1%	0.78 [0.61, 1.00]	-
Subtotal (95% CI)		1802		86408	28.1%	0.76 [0.67, 0.85]	•
Total events	244		17156				
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.59	, df = 3 (F	= 0.90);	$ ^2 = 0\%$		
Test for overall effect:	Z = 4.62 (P < 0.0	0001)				
1.1.2 moderate level							
Balato 2015	14	400	29	498	3.5%	0.60 [0.32, 1.12]	
Barrea 2015	2	41	3	41	0.6%	0.67 [0.12, 3.78]	
Frankel 2012	684	1068	51839	85587	12.5%	1.06 [1.01, 1.11]	
Milčić 2017	71	244	66	163	8.5%	0.72 [0.55, 0.94]	
Torres 2014	29	90	50	160	6.5%	1.03 [0.71, 1.50]	
Subtotal (95% CI)		1843		86449	31.7%	0.88 [0.69, 1.13]	•
Total events	800		51987				
Heterogeneity: Tau ² =	0.04; Chi ²	= 11.2	7, df = 4	(P = 0.02)	; l ² = 65%		
Test for overall effect:	Z = 1.00 (P = 0.3	2)	9. S.S.MA			
1.1.3 low level							
Balato 2015	18	400	55	400	4.6%	0.33 [0.20, 0.55]	
Barrea 2015	39	41	36	41	11.3%	1.08 [0.95, 1.24]	+
Frankel 2012	222	1068	16739	85587	11.6%	1.06 [0.94, 1.20]	+
Milčić 2017	147	244	70	163	9.9%	1.40 [1.14, 1.72]	-
Torres 2014	17	90	10	90	2.8%	1.70 [0.82, 3.51]	<u> </u>
Subtotal (95% CI)		1843		86281	40.3%	1.01 [0.78, 1.32]	•
Total events	443		16910				
Heterogeneity: Tau ² =	0.06; Chi ²	= 29.2	5, df = 4	(P < 0.000	001); l ² = 8	6%	
Test for overall effect:	Z = 0.11 (P = 0.9	2)				
Total (95% CI)		5488		259138	100.0%	0.89 [0.78, 1.03]	•
Total events	1487		86053				2 2 3 3 2 2 2 3
Heterogeneity: Tau ² =	0.04; Chi ²	= 73.7	5, df = 13	B (P < 0.00	0001); l ² =	82%	0.1 0.2 0.5 1 2 5 10
Test for overall effect:	Z = 1.58 (P = 0.1	1)				control psoriasis
Test for subaroup diffe		hi2 - 4	11	(D - 0 1	1 12 - 54	70/	control psonasis

Figure 2. Meta-analysis of the impact on exercise levels of patients with psoriasis and healthy controls. The RR in different exercise levels of psoriatic patients and healthy controls. The point estimate (center of each blue square) and statistical size (proportional area of the square) are represented. Horizontal lines indicate 95% confidence intervals. The subtotal and total pooled RR (diamond) was calculated using a random-effects model. RR=risk ratio.

Study or Subgroup	Mean	soriasis SD	Total	Mean	Control SD	Total	Weight	Std. Mean Difference IV. Random, 95% Cl				fferen 95%	
Sector Sector	67	Part Internet			0.0053	200.00		and the second second second		v, na		00/0	
Balato 2015	4	10.3	400	4.2	9.3	498	39.1%	-0.02 [-0.15, 0.11]			Ī		
Torres 2014	3,341.5	3,096.8	90	4,688.7	3,186.1	160	26.8%	-0.43 [-0.69, -0.16]					
Wilson 2013	24	17.3	117	27.7	51.8	4199	34.1%	-0.07 [-0.26, 0.11]			1		
Total (95% CI)			607			4857	100.0%	-0.15 [-0.35, 0.06]			٠		
Heterogeneity: Tau ² =	0.02; Chi ²	= 7.46, d	f = 2 (P	= 0.02);	² = 73%			57 10 100 <u>-</u>	-2	-1	0	1	

Figure 3. Meta-analysis of the impact on exercise minutes of patients with psoriasis and healthy controls. The SMD in different exercise levels of psoriatic patients and healthy controls. The point estimate (center of each blue square) and statistical size (proportional area of the square) are represented. Horizontal lines indicate 95% confidence intervals. The subtotal and total SMD (diamond) were calculated using a random-effects model. SMD=standard mean difference.




Figure 4. Meta-analysis of the impact on exercise scores of patients with psoriasis and healthy controls. The SMD in different exercise scores of psoriatic patients and healthy controls. The point estimate (center of each blue square) and statistical size (proportional area of the square) are represented. Horizontal lines indicate 95% confidence intervals. The subtotal and total SMD (diamond) were calculated using a random-effects model. SMD=standard mean difference.

studies have focused on identifying protective factors for psoriasis. Exercise is one such factor, but the relationship between exercise and psoriasis remains to be further explored. Numerous studies have proven that psoriasis is closely associated with physical activity. The theory that only vigorous physical activity can decrease the risk of incident psoriasis was introduced by Frankel.^[40] Other studies have shown that the level of physical activity could influence the prevalence of psoriasis. Lewis-Beck

2.1.1 vigorous level to low level in psoriasis Balato 2015 12 400 18 400 6.1% 0.67 [0.33, 1.37] Frankel 2012 162 1068 222 1068 6.4% 0.73 [0.61, 0.88] Kavii 1985 921 14667 5142 14667 6.4% 0.18 [0.17, 0.19] Mičić 2017 26 244 147 244 6.3% 0.18 [0.12, 0.26] Torres 2014 44 90 17 90 6.3% 2.59 [1.61, 4.17] Subtotal (95% CI) 16469 16469 31.5% 0.52 [0.20, 1.31] Total events 1165 5546 Heterogeneity: Tau ² = 1.07; Chi ² = 315.39, df = 4 ($P < 0.00001$); l ² = 99% Test for overall effect: Z = 1.40 ($P = 0.16$) 2.1.2 moderate level in psoriasis Balato 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavii 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Mičić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 ($P < 0.00001$); l ² = 98% Test for overall effect: Z = 0.09 ($P = 0.93$) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.37 (0.24, 0.20, 0.27] Kavii 1985 CI) 16540 7.70 0.98 ($D = 5.09$ ($P < 0.00001$); l ² = 98% Test for overall effect: Z = 0.09 ($P = 0.93$) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.37 (0.24, 0.20, 0.27] Kavii 1995 CI) 16469 114667 8389 14667 6.4% 0.11 (0.10, 0.12] Mičić 2017 26 244 71 244 6.3% 0.37 (0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 116469 31.5% 0.40 [0.18, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27]	Study or Subgroup	Higher		Lower		Weight	Risk Ratio	Risk Ratio M-H. Random, 95% Cl
Balato 2015 12 400 18 400 6.1% 0.67 [0.33, 1.37] Frankel 2012 162 1068 222 1068 6.4% 0.73 [0.61, 0.88] Mičić 2017 26 244 147 244 6.3% 0.18 [0.17, 0.19] Mičić 2017 26 244 147 244 6.3% 0.18 [0.17, 0.19] Mičić 2017 26 244 147 244 6.3% 0.18 [0.12, 0.26] Torres 2014 44 90 17 90 6.3% 2.59 [1.61, 4.17] Subtotal (95% CI) 16469 16469 31.5% 0.52 [0.20, 1.31] Total events 1165 5546 Heterogeneity: Tau ² = 1.07; Chi ² = 315.39, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 1.40 (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 411 39 411 5.4% 0.05 [0.01, 0.20] Frankel 2012 644 1068 222 1068 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.38; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavii 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Mičić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Total events 1165 9187 Heterogeneity: Tau ² = 0.39; Chi ² = 312.88, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.88, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27]					Total	Treight	III-II, Rundolli, 0070 O	
Frankel 2012 162 1068 222 1068 6.4% 0.73 [0.61, 0.88] Kavli 1985 921 14667 5142 14667 6.4% 0.18 [0.17, 0.19] Milčić 2017 26 244 147 244 6.3% 0.18 [0.12, 0.26] Torres 2014 44 90 17 90 6.3% 2.59 [1.61, 4.17] Subtotal (95% CI) 16469 116469 31.5% 0.52 [0.20, 1.31] Total events 1165 5546 Heterogeneity: Tau ² = 1.07; Ch ² = 315.39, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 1.40 (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Ch ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 1 2 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 (0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 49 90 29 90 6.5% 0.37 [0.24, 0.55] Torres 2014 49 90 29 90 6.5% 0.37 [0.40, 0.56] Subtotal (95% CI) 16649 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Ch ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27]					400	6 1%	0 67 10 33 1 371	
Kavii 1985 921 14667 5142 14667 6.4% 0.18 [0.17, 0.19] Mičić 2017 26 244 147 244 6.3% 0.18 [0.12, 0.26] Torres 2014 44 90 17 90 6.3% 2.59 [1.61, 4.17] Subtotal (95% CI) 16469 16469 31.5% 0.52 [0.20, 1.31] Total events 1165 5546 Heterogeneity: Tau ² = 1.07; Ch ² = 315.39, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 1.40 (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavii 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Mičić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Ch ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavii 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Mičić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Ch ² = 312.88, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Ch ² = 312.88, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total events 11519 20217 Total events 11519 20217 Heterogeneity: Tau ² = 0.79; Ch ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20217								-
Mikčić 2017 26 244 147 244 6.3% 0.18 [0.12, 0.26] Torres 2014 44 90 17 90 6.3% 2.59 [1.61, 4.17] Subtotal (95% Cl) 16469 16469 31.5% 0.52 [0.20, 1.31] Total events 1165 5546 Heterogeneity: Tau ² = 1.07; Ch ² = 315.39, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 1.40 (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Mikčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% Cl) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Ch ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.36 [0.40, 1.83] Frankel 2012 162 1068 664 1068 6.4% 0.24 [0.20, 0.27] Kavil 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Mikčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% Cl) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Ch ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% Cl) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317								
Torres 2014 44 90 17 90 6.3% 2.59 [1.61, 4.17] Subtotal (95% CI) 16469 16469 31.5% 0.52 [0.20, 1.31] Total events 1165 5546 Heterogeneity: Tau ² = 1.07; Chi ² = 315.39, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 1.40 (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavii 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 1244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavii 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Test for overall effect: Z = 2.23 (P = 0.03) Total events 1165 9187 Test for overall effect: Z = 2.23 (P = 0.03) Total events 11519 20317								-
Subtotal (95% Cl) 16469 16469 31.5% 0.52 [0.20, 1.31] Total events 1165 5546 Heterogeneity: Tau ² = 1.07; Ch ² = 315.39, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 1.40 (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 411 39 41 5.4% 0.055 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavii 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milôić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% Cl) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Ch ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavii 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milôić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% Cl) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Ch ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total events 11519 20317 Heterogeneity: Tau ² = 0.79; Ch ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% Cl) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317								
Heterogeneity: Tau ² = 1.07; Chi ² = 315.39, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 1.40 (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 1 4 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavil 1985 3389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% Cl) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 1 2 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 (0.20, 0.27] Kavil 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Totres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% Cl) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% Cl) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 0.79; Chi ² = 1062 32 df = 15 (P < 0.00001); l ² = 100%								•
Test for overall effect: $Z = 1.40$ (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 0.67 Chi ² = 10964 23 df = 16 (P < 0.00001); l ² = 100%		1165		5546				201
Test for overall effect: $Z = 1.40$ (P = 0.16) 2.1.2 moderate level to low level in psoriasis Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 0.67 Chi ² = 10962 3.4 ff = 16 (P < 0.00001); l ² = 100%	Heterogeneity: Tau ² =	1.07; Chi2	= 315.3	9, df = 4	(P < 0.00	0001); l ² =	99%	
Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); I ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67 Chi ² = 10964 20.37 (0.24 0.056) Total events 11519 20317								
Balato 2015 14 400 18 400 6.1% 0.78 [0.39, 1.54] Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); I ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67 Chi ² = 10964 20.37 (0.24 0.056) Total events 11519 20317								
Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavil 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); I ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavil 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27]	2.1.2 moderate level	to low lev	el in pse	oriasis				
Barrea 2015 2 41 39 41 5.4% 0.05 [0.01, 0.20] Frankel 2012 684 1068 222 1068 6.4% 3.08 [2.72, 3.49] Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); I ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27]	Balato 2015	14	400	18	400	6.1%	0.78 [0.39, 1.54]	-+
Kavli 1985 8389 14667 5141 14667 6.4% 1.63 [1.59, 1.67] Milčić 2017 71 244 147 244 6.4% 0.48 [0.39, 0.60] Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67; Chi ² = 1064 23 df = 15 (P < 0.00001); l ² = 100%	Barrea 2015	2	41	39	41	5.4%		
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Frankel 2012	684	1068	222	1068	6.4%	3.08 [2.72, 3.49]	
Torres 2014 29 90 17 90 6.2% 1.71 [1.01, 2.88] Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčíć 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2 6.7; Chi ² = 1064 23 df = 15 (P < 0.00001); l ² = 100%	Kavli 1985	8389	14667	5141	14667	6.4%	1.63 [1.59, 1.67]	
Subtotal (95% CI) 16510 16510 37.0% 0.98 [0.58, 1.65] Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavii 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) 1054 9.056 [0.25, 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] <t< td=""><td>Milčić 2017</td><td>71</td><td>244</td><td>147</td><td>244</td><td>6.4%</td><td>0.48 [0.39, 0.60]</td><td>-</td></t<>	Milčić 2017	71	244	147	244	6.4%	0.48 [0.39, 0.60]	-
Total events 9189 5584 Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); l ² = 98% Test for overall effect: Z = 0.09 (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) 154 Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2 67; Chi ² = 10664 23. df = 15 (P < 0.00001); l ²	Torres 2014	29	90	17	90	6.2%	1.71 [1.01, 2.88]	-
Heterogeneity: Tau ² = 0.36; Chi ² = 244.75, df = 5 (P < 0.00001); I ² = 98% Test for overall effect: $Z = 0.09$ (P = 0.93) 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% Cl) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% Cl) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317	Subtotal (95% CI)		16510		16510	37.0%	0.98 [0.58, 1.65]	+
Test for overall effect: $Z = 0.09 (P = 0.93)$ 2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavii 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau² = 0.79; Chi² = 312.98, df = 4 (P < 0.00001); l² = 99%	Total events	9189		5584				
2.1.3 vigorous level to moderate level in psoriasis Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavil 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2 67: Chi ² = 10664 23. df = 15 (P < 0.00001): l ² = 100%	Heterogeneity: Tau ² =	0.36; Chi ²	= 244.7	5, df = 5	(P < 0.00	0001); l ² =	98%	
Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67; Chi ² = 10664 23, df = 15 (P < 0.00001); I ² = 100%	Test for overall effect:	Z = 0.09 (P = 0.93)				
Balato 2015 12 400 14 400 6.1% 0.86 [0.40, 1.83] Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67; Chi ² = 10664 23, df = 15 (P < 0.00001); I ² = 100%								
Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavli 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total events 11519 20317 Heterogeneity: Tau ² = 2 67; Chi ² = 10664 23 df = 15 (P < 0.00001); I ² = 100%	2.1.3 vigorous level t							
Frankel 2012 162 1068 684 1068 6.4% 0.24 [0.20, 0.27] Kavii 1985 921 14667 8389 14667 6.4% 0.11 [0.10, 0.12] Milčić 2017 26 244 71 244 6.3% 0.37 [0.24, 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05, 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau² = 0.79; Chi² = 312.98, df = 4 (P < 0.00001); l² = 99%	Balato 2015				400			
Milčić 2017 26 244 71 244 6.3% 0.37 [0.24 , 0.55] Torres 2014 44 90 29 90 6.3% 1.52 [1.05 , 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18 , 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25 , 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25 , 1.27] Heterogeneity: Tau ² = 2.67; Chi ² = 10964 23.07 Heterogeneity: Tau ² = 2.67; Chi ² = 10964 23.07								•
Torres 2014 44 90 29 90 6.3% 1.52 [1.05 , 2.19] Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18 , 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); I ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25 , 1.27] Total (95% CI) 49448 49448 100.0% 0.56 [0.25 , 1.27] Heterogeneity: Tau ² = 2 67; Chi ² = 10964 23 df = 15 (P < 0.00001); I ² = 100%								
Subtotal (95% CI) 16469 16469 31.5% 0.40 [0.18, 0.90] Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67; Chi ² = 10964 23. df = 15 (P < 0.00001); l ² = 100%								-
Total events 1165 9187 Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: $Z = 2.23$ (P = 0.03) Total (95% Cl) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67; Chi ² = 10064 23. df = 15 (P < 0.00001); l ² = 100%		44		29				
Heterogeneity: Tau ² = 0.79; Chi ² = 312.98, df = 4 (P < 0.00001); l ² = 99% Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau ² = 2.67; Chi ² = 10964 23, df = 15 (P < 0.00001); l ² = 100%			16469		16469	31.5%	0.40 [0.18, 0.90]	· · · · · · · · · · · · · · · · · · ·
Test for overall effect: Z = 2.23 (P = 0.03) Total (95% CI) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterographity: Tau ² = 2.67; Cbi ² = 10964 23 df = 15 (P < 0.00001); I ² = 100%			LUCES DEL					
Total (95% Cl) 49448 49448 100.0% 0.56 [0.25, 1.27] Total events 11519 20317 Heterogeneity: Tau² = 2.67: Cbi² = 10964 23. cf = 15 (P < 0.00001): l² = 100%					(P < 0.00)	0001); l ² =	99%	
Total events 11519 20317 Heterogeneity: $Tau^2 = 2.67$; Chi ² = 10964 23, cf = 15 (P < 0.00001); l ² = 100%	Test for overall effect:	Z = 2.23 (P = 0.03)				
Total events 11519 20317 Heterogeneity: Tau ² = 2.67: Chi ² = 10964 23. df = 15.(P < 0.00001): l ² = 100%	Total (95% CI)		49448		49448	100.0%	0.56 [0.25, 1.27]	•
Heterogeneity: Tau ² = 2.67: Chi ² = 10964.23. df = 15 (P < 0.00001): l ² = 100%		11519		20317				
			= 10964		15 (P <	0.00001):	$l^2 = 100\%$	0.001 0.1 1 10 1000

Figure 5. Meta-analysis of patients with psoriasis with different exercise levels. The point estimate (center of each blue square) and statistical size (proportional area of the square) are represented. Horizontal lines indicate 95% confidence intervals. The subtotal and total pooled RR (diamond) was calculated using a random-effects model. RR=risk ratio.




Figure 6. Meta-analysis of healthy controls with different exercise levels. The point estimate (center of each blue square) and statistical size (proportional area of the square) are represented. Horizontal lines indicate 95% confidence intervals. The subtotal and total pooled RR (diamond) was calculated using a random-effects model. RR=risk ratio.

et al^[30] conducted a questionnaire survey among 199 patients with moderate-to-severe psoriasis and showed that 72.36% of patients reported impaired levels of activity because of psoriasis. Another study^[26] reported that sporting activities were significantly (P < .001) affected among patients with mild, moderate, and severe psoriasis. Additionally, in a study by Leino et al,^[28] 23.7% of patients had reduced their sporting activities while

30.2% had stopped completely. In accordance with these results, our meta-analysis exposes the relationship between the degree of exercise and prevalence of psoriasis.

As shown by the large number of articles published in recent years, the negative effects of moderate-to-severe psoriasis on both work and physical activity are becoming increasingly credible. Our current meta-analysis extended the data of the earlier studies




Figure 7. Meta-analysis of the frequency of regular exercise in patients with psoriasis and healthy controls. The point estimate (center of each blue square) and statistical size (proportional area of the square) are represented. Horizontal lines indicate 95% confidence intervals. The subtotal and total pooled RR (diamond) was calculated using a fixed-effects model. RR=risk ratio.

by investigating the correlation between psoriasis and physical activity. The main contents of the included studies were about the prevalence of psoriasis except for that of Frankel,^[40] which aimed to interpret the association of physical activity and risk of incident psoriasis. Although prevalence rate and incidence rate are different, prevalence rate is dependent on the incidence rate and duration. As the incidence rate increases, the rate of prevalence increases correspondingly. Therefore, we included this study into our meta-analysis. We recruited a group of patients with psoriasis (n = 17834), and another group of healthy subjects without psoriasis (n = 131665). Then, we compared the two groups directly and analyzed subgroups by using a range of data extracted from the previous publications identified, including exercise duration, exercise score (the Godin Leisure-Time Exercise Questionnaire and Quality of life questionnaire: SF-36) and the frequency of regular exercising in the past. We classified the intensity of exercise into low, moderate, and vigorous. Our results showed a causal link between physical activity and prevalence of psoriasis. Psoriasis will reduce vigorous exercising and only vigorous physical activity will decrease the prevalence of psoriasis. Furthermore, we believe that strenuous physical activity is related to a reduction in the prevalence of psoriasis. Otherwise, regular bouts of physical activity can improve psoriatic skin lesions due to the benefits of sunlight during outdoor exercises.^[49]

It is difficult to precisely interpret the data shown in Figure 4, which illustrates the differences in exercise duration between patients with psoriasis and normal controls (RR: 0.56; 95% CI: -0.89 to 2.01; P=.45). This is because exercise time cannot be directly translated into the intensity of the physical activity, for example, longer exercise duration does not necessarily indicate a higher severity of exercise. Exercise intensity refers to the degree of physical stimulation of the body. A previous study^[39] used a questionnaire or an analogue scale, which uses a combination of physical and mental health scores, with higher scores indicating better function. The authors of that study believed that patients with mild-to-moderate psoriasis had a lifestyle that involved physical activity. We understand that patients with psoriasis tend to exercise more than the controls, and this may be attributed to patients receiving advice from physicians regarding moderate exercise and therefore have increased awareness of the significance of exercise.

Finally, it is important to note that traditional meta-analyses are often limited by confounding factors, such as heterogeneity and publication bias. The diversity of designs and the inherent bias of observational studies make it challenging to examine the methodological quality. Because we analyzed a relatively small number of publications in our meta-analysis, there is a high risk of statistical heterogeneity ($I^2 > 50\%$). In addition, factors such as obesity, age, gender, and economic conditions will affect patients' ability to exercise and therefore these should be considered as potential bias in this paper. In order to reduce this risk, we performed subgroup analyses. Regardless of potential publication bias, we applied strict inclusion and exclusion criteria, which should reduce the impact of such bias. Therefore, the aforementioned potential limitations must be considered when interpreting the study conclusions.

Author contributions

Conceptualization: Rong Xu, Xin Li.

Data curation: Qi Zheng, Ya Nan Zhang.

Formal analysis: Xiao Ying Sun, Xiao Miao, Tian Ma.

Investigation: Xin Li. Methodology: Rong Xu. Project administration: Bin Li. Software: Tian Ma, Ya Nan Zhang. Supervision: Xiao Miao. Validation: Qi Zheng. Writing – original draft: Qi Zheng, Xiao Ying Sun.

Writing - review & editing: Hong Jin Li, Bin Li, Xin Li.

References

- Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 2009;60:218–24.
- [2] Takahashi H, Satoh K, Takagi A, et al. Economic burden of psoriatic patients in Japan: analysis from a single outpatient clinic. J Dermatol 2017;44:1024–6.
- [3] Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Archives of dermatology 2011;147: 419–24.
- [4] Raychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000;66:348–52.
- [5] Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. Arch Dermatol Res 2017;309:225–8.
- [6] Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol 2014;70:691–8.
- [7] Radner H, Lesperance T, Accortt NA, et al. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res 2016;69:1510–8.
- [8] Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010;163:586–92.
- [9] Prizment AE, Alonso A, Folsom AR, et al. Association between psoriasis and incident cancer: the Iowa's Women's Health Study. Cancer Causes Control 2011;22:1003–10.
- [10] Ogdie A, Harter L, Shin D, et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann Rheum Dis 2017;76:882–5.
- [11] Modalsli EH, Asvold BO, Romundstad PR, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway. Br J Dermatol 2017;176:1162–9.
- [12] Chiu HY, Wang IT, Huang WF, et al. Increased risk of avascular necrosis in patients with psoriatic disease: a nationwide population-based matched cohort study. J Am Acad Dermatol 2016;76:903–10.e1.
- [13] Liakou AI, Zouboulis CC. Links and risks associated with psoriasis and metabolic syndrome. Psoriasis 2015;5:125–8.
- [14] Li X, Kong L, Li F, et al. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PloS One 2015;10:e0145221.
- [15] Li X, Miao X, Wang H, et al. Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95:e3676.
- [16] Shalom G, Dreiher J, Cohen A. Psoriasis and obstructive sleep apnea. Int J Dermatol 2016;55:e579–84.
- [17] Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614–21.
- [18] LØrincz K, Haluszka D, Kiss N, et al. Voluntary exercise improves murine dermal connective tissue status in high-fat diet-induced obesity. Arch Dermatol Res 2017;309:209–15.
- [19] Edwards MK, Blaha MJ, Loprinzi PD. Influence of sedentary behavior, physical activity, and cardiorespiratory fitness on the atherogenic index of plasma. J Clin Lipidol 2017;11:119–25.
- [20] Flood A, Waddington G, Cathcart S. Examining the relationship between endogenous pain modulation capacity and endurance exercise performance. Res Sports Med 2017;25:300–12.
- [21] Tsukui S, Kanda T, Nara M, et al. Moderate-intensity regular exercise decreases serum tumor necrosis factor-alpha and HbA1c levels in healthy women. Int J Obes Relat Metab Disord 2000;24:1207–11.
- [22] Straczkowski M, Kowalska I, Dzienis-Straczkowska S, et al. Changes in tumor necrosis factor-alpha system and insulin sensitivity during an

exercise training program in obese women with normal and impaired glucose tolerance. Eur J Endocrinol 2001;145:273–80.

- [23] Wurz A, Brunet J. The effects of physical activity on health and quality of life in adolescent cancer survivors: a systematic review. JMIR Cancer 2016;2:e6.
- [24] Pence BD, Woods JA. Exercise, obesity, and cutaneous wound healing: evidence from rodent and human studies. Adv Wound Care 2014;3: 71–9.
- [25] Huang HC, Wong MK, Yang YH, et al. Impact of playing exergames on mood states: a randomized controlled trial. Cyberpsychology Behav Soc Netw 2017;20:246–50.
- [26] Al-Mazeedi K, El-Shazly M, Al-Ajmi HS. Impact of psoriasis on quality of life in Kuwait. Int J Dermatol 2006;45:418–24.
- [27] Korman NJ, Zhao Y, Pike J, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol 2016;41:514–21.
- [28] Leino M, Mustonen A, Mattila K, et al. Perceived impact of psoriasis on leisure-time activities. Eur J Dermatol 2014;24:224–8.
- [29] Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS One 2012;7:e52935.
- [30] Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderateto-severe psoriasis using structural equation modeling. Patient Prefer Adherence 2013;7:199–205.
- [31] Wilson PB, Bohjanen KA, Ingraham SJ, et al. Psoriasis and physical activity: a review. J Eur Acad Dermatol Venereol 2012;26:1345–53.
- [32] Schmitt-Egenolf M. Physical activity and lifestyle improvement in the management of psoriasis. Br J Dermatol 2016;175:452–3.
- [33] Ahdout J, Kotlerman J, Elashoff D, et al. Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis. Clin Exp Dermatol 2012;37:477–83.
- [34] Balato N, Megna M, Palmisano F, et al. Psoriasis and sport: a new ally? J Eur Acad Dermatol Venereol 2015;29:515–20.
- [35] Do YK, Lakhani N, Malhotra R, et al. Association between psoriasis and leisure-time physical activity: findings from the National Health and Nutrition Examination Survey. J Dermatol 2015;42:148–53.

- [36] Osmancevic A, Landin-Wilhelmsen K, Larkö O, et al. Risk factors for osteoporosis and bone status in postmenopausal women with psoriasis treated with UVB therapy. Acta Derm Venereol 2008;88:240–6.
- [37] Torres T, Alexandre JM, Mendonça D, et al. Levels of physical activity in patients with severe psoriasis: a cross-sectional questionnaire study. Am J Clin Dermatol 2014;15:129–35.
- [38] Wilson PB. Moderate-to-vigorous physical activity in individuals with psoriasis: associations with body surface area and subjective disease severity. G Ital Dermatol Venereol 2013;148:485–92.
- [39] Demirel R, Genc A, Ucok K, et al. Do patients with mild to moderate psoriasis really have a sedentary lifestyle? Int J Dermatol 2013;52: 1129–34.
- [40] Frankel HC, Han J, Li T, et al. The association between physical activity and the risk of incident psoriasis. Arch Dermatol 2012;148:918–24.
- [41] Kavli G, Førde OH, Arnesen E, et al. Psoriasis: familial predisposition and environmental factors. Br Med J (Clin Res Ed) 1985;291:999–1000.
- [42] Barrea L, Macchia PE, Tarantino G, et al. Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire. J Transl Med 2015;13:303.
- [43] Milčić D, Janković S, Vesić S, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol 2017;92:46–51.
- [44] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
- [45] Zou L, Lonne-Rahm SB, Helander A, et al. Alcohol intake measured by phosphatidylethanol in blood and the lifetime drinking history interview are correlated with the extent of psoriasis. Dermatology 2015;230:375–80.
- [46] Owczarczyk-Saczonek AB, Nowicki R. The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postepy Dermatol Alergol 2015;32:331–6.
- [47] Jensen P, Skov L. Psoriasis and Obesity. Dermatology 2016;232:633-9.
- [48] Skoie IM, Dalen I, Ternowitz T, et al. Fatigue in psoriasis: a controlled study. Br J Dermatol 2017;177:505–12.
- [49] Søyland E, Heier I, Rodríguez-Gallego C, et al. Sun exposure induces rapid immunological changes in skin and peripheral blood in patients with psoriasis. Br J Dermatol 2011;164:344–55.